PTN — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-13

• Our strategy is focused on advancing a differentiated portfolio of melanocortin receptor-targeted therapeutics, with an emphasis on MC4R agonists for rare neuroendocrine obesity disorders and other indications with significant unmet medical need. Key elements include:

• ●Advancing a focused MC4R pipeline: Maintain a lean, execution-oriented organization to discover, develop, and advance MC4R selective agonists for rare MC4R pathway diseases, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome;

• ●Leveraging strategic partnerships: Establish and expand collaborations with pharmaceutical and biotechnology partners to support the development, manufacturing, and commercialization of our product candidates, including applications beyond;

• ●Disciplined capital strategy: Fund operations through a combination of non-dilutive sources— including cash flows from the licensing and sale of Vyleesi, our collaboration with Boehringer Ingelheim, and other licensing arrangements, supplemented by prudent, opportunistic equity financings, with a f…

• ●Driving clinical and regulatory execution: Advance selected product candidates through clinical development and pursue regulatory approvals in targeted indications.

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• ● Maintaining a team to create, develop and commercialize MC4R agonists addressing unmet medical needs for rare MC4R pathway diseases;

• ● Entering into strategic alliances and partnerships with companies to facilitate the development, manufacture, marketing, sale, and distribution of product candidates that we are developing, including products for indications other than obesity;

• ● Partially funding our product development programs with the cash flow generated from the sale of Vyleesi to Cosette, our agreement with Boehringer Ingelheim, and existing license agreements, as well as any future research, collaboration, or license agreements; and

• ● Completing development and seeking regulatory approval of certain of our product candidates.

• Revenues – For the three and six months ended December 31, 2025, we recognized $116,036 and $8,963,586 in collaboration and license revenue compared to $0 for the three and six months ended December 31, 2024. The increase in collaboration and license revenue is related to the BI Agreement which cons…

Text added vs the prior filing · source: 10-Q · 2026-05-13

• We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business.

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business. On February 13, 2025, a complaint was filed in the Supreme Court of the State of New York, County of New York, captioned H.C. Wainwright & Co., LLC (“Wainwright”) v. Palatin…